Internal Medicine
| 2 min read
Schering-Plough Research Institute joins in the scientific collaboration that Hurel has convened to develop “human-on-a-chip” technology.
| 2 min read
Avalon and ChemDiv are combining their technologies to seek small molecules active against cancer.
| 2 min read
LifeStem Inc., a subsidiary of CalbaTech Inc., introduced a program that collects and banks adult stem cells from two tissue sources in healthy individuals.
| 2 min read
Scientists scanned the phosphoprotein profile of acute myeloid leukemia (AML), identifying a novel mutant protein kinase (JAK3) that may drive AML progression
| 2 min read
Lab mice may have competition in modeling human cancer, as scientists at Phylonix Pharmaceuticals successfully modeled various stages of tumor development in zebrafish.
| 2 min read
Elara Pharmaceuticals will be dedicated to drug development and following up on promising small molecule anti-cancer leads.
| 2 min read
The transaction is expected to close in Q3 2006 and to be dilutive to Gilead’s 2006 and 2007 earnings.
| 3 min read
For good or for ill, the Canadian government (like many others) tightly regulates the prices that companies can charge for various drugs. And for the most part, companies have just had to take it—-putting it down to the cost of doing business in Canada. Until recently, that is.
In June, Bristol-Myers Squibb Canada announced it would not make its anti-cancer treatment Erbitux available to Canadians because it had been unable to agree on a suitable price for the drug with Canada’s Patented Medicine Prices Review Board. At the time, public relations director for BMS Canada Marc Osborne said the government’s price was “not in line with the innovation it brings to patients.”
| 3 min read
Every now and then it helps for me to simply off-load a few random thoughts that have occurred to me over the past few months. This is one of those times.
| 1 min read
As analytical tools improve, the use of metabolic information in drug discovery and development increases.
| 2 min read
Biomachines announced the formation of a new division--Applied Proteomics Services--from a collaboration with UMass\'s Proteomic Fractionation Group.
